Home › RLT targets by cancer › Ovarian Cancer
Radioligand therapy · Ovarian Cancer

Radioligand Therapy Targets in Ovarian Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in ovarian cancer (including high-grade serous ovarian carcinoma). 4,528 show detectable protein staining. Established and emerging radioligand targets expressed in ovarian cancer include EPCAM, STEAP2, HER3 (ERBB3) and c-MET (MET). Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own ovarian cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank ovarian cancer targets free

Established and emerging radioligand targets in ovarian cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in ovarian cancer:

TargetIHC in ovarian cancer% positiveInternalizes
EPCAMHigh (0.92)100%—
STEAP2High (0.82)100%—
HER3 (ERBB3)High (0.73)100%yes
c-MET (MET)High (0.72)100%yes
Mesothelin (MSLN)High (0.61)83%yes
ITGAVHigh (0.58)100%—
B7-H3 (CD276)High (0.53)100%—
Nectin-4 (NECTIN4)Medium (0.48)100%no
FAPMedium (0.47)60%yes
Claudin 18.2 (CLDN18)Medium (0.33)33%uncertain
TMEFF2Medium (0.33)75%—
ITGB6Medium (0.21)46%—
HER2 (ERBB2)Low (0.18)27%yes
CEA (CEACAM5)Low (0.17)30%—
EGFRLow (0.11)25%yes
SSTR2Low (0.08)25%yes
TROP2 (TACSTD2)Low (0.06)8%uncertain
DLK1Low (0.03)9%—

Top cell-surface targets for ovarian cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in ovarian cancer% positiveInternalizesClinical stage
1IGF1R
insulin like growth factor 1 receptor
High (0.89)100%yesFDA-Approved
2c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
High (0.72)100%yesFDA-Approved
3S1PR1
sphingosine-1-phosphate receptor 1
High (0.61)100%yesFDA-Approved
4HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.73)100%yesFDA-Approved
5AMFR
autocrine motility factor receptor
High (1.00)100%yesDiscovery
6GPR139
G protein-coupled receptor 139
High (0.97)100%yesDiscovery
7IRAK4
interleukin 1 receptor associated kinase 4
High (0.81)100%yesClinical
8NOTCH1
notch receptor 1
High (0.75)100%yesClinical
9MUC16
mucin 16, cell surface associated
High (1.00)100%—Clinical
10NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.80)100%uncertainFDA-Approved
11MST1R
macrophage stimulating 1 receptor
High (0.64)100%yesFDA-Approved
12FGFR1
fibroblast growth factor receptor 1
High (0.61)100%yesFDA-Approved
13HRH4
histamine receptor H4
High (0.75)100%yesClinical
14CYSLTR2
cysteinyl leukotriene receptor 2
High (0.75)92%yesDiscovery
15EPHB2
EPH receptor B2
High (0.72)100%uncertainFDA-Approved
16KCNG1
potassium voltage-gated channel modifier subfamily G member 1
High (0.89)100%—FDA-Approved
17PTPN13
protein tyrosine phosphatase non-receptor type 13
High (0.83)100%yesDiscovery
18PTGS1
prostaglandin-endoperoxide synthase 1
High (0.83)100%—FDA-Approved
19CHRNA7
cholinergic receptor nicotinic alpha 7 subunit
High (0.67)100%yesClinical
20Mesothelin (MSLN)
mesothelin
High (0.61)83%yesClinical
21FZD6
frizzled class receptor 6
High (0.83)100%yesDiscovery
22LSR
lipolysis stimulated lipoprotein receptor
High (0.83)100%yesDiscovery
23TRPV2
transient receptor potential cation channel subfamily V member 2
High (0.91)100%uncertainDiscovery
24NOTCH2
notch receptor 2
High (0.58)100%yesClinical
25SCTR
secretin receptor
High (0.91)100%uncertainDiscovery

Internalizing receptors in ovarian cancer

Targets expressed in ovarian cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

IGF1R · c-MET (MET) · S1PR1 · HER3 (ERBB3) · AMFR · GPR139 · IRAK4 · NOTCH1 · MST1R · FGFR1 · HRH4 · CYSLTR2

Ovarian Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in ovarian cancer. Clinical precedent lowers development risk but usually means more competition:

IGF1R · c-MET (MET) · S1PR1 · HER3 (ERBB3) · IRAK4 · NOTCH1 · MUC16 · NR3C2 · MST1R · FGFR1 · HRH4 · EPHB2

How these ovarian cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in ovarian cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank ovarian cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free ovarian cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist ovarian cancer targets for your program · 5 free analyses, no card Rank ovarian cancer targets free